Results for tag: "Primary Gastric Lymphoma Drug"

Primary Gastric Lymphoma (PGL) is a rare type of non-Hodgkin's lymphoma that affects the stomach. It is a type of B-cell lymphoma, which is a cancer of the white blood cells. Treatment for PGL typically involves chemotherapy, radiation therapy, and/or surgery. Drug therapy is also used to treat PGL, and the primary gastric lymphoma drug market is focused on providing effective treatments for this type of cancer. The primary gastric lymphoma drug market is composed of a variety of drugs, including monoclonal antibodies, small molecule drugs, and targeted therapies. These drugs are designed to target specific proteins or pathways in the body that are involved in the development and progression of PGL. The drugs are used to reduce the size of the tumor, reduce symptoms, and improve overall survival. The primary gastric lymphoma drug market is highly competitive, with many companies offering innovative treatments for PGL. Some of the major players in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more